You haven't searched anything yet.
Company Summary:
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, please visit http://www.leaptx.com.
General Responsibilities:
Leap Therapeutics, Inc. is seeking a highly skilled and experienced professional to join our executive team as the Vice President of Quality Assurance. The successful candidate will play a crucial role in ensuring the highest standards of quality and compliance in all aspects of our pharmaceutical operations. The VP of Quality Assurance will lead a dedicated team across all GxP areas and collaborate across departments to maintain and improve the quality management systems, drive regulatory compliance, and foster a culture of continuous improvement. Ideal candidate will have experience in a growing biopharmaceutical company managing clinical development in a vendor outsourcing model.
Key Responsibilities
Qualifications
:
Full Time
Pharmaceutical
$210k-280k (estimate)
02/17/2024
05/13/2024
leaptx.com
EAST CAMBRIDGE, MA
25 - 50
2011
CHRISTOPHER K MIRABELLI
<$5M
Pharmaceutical